Syngene International Limited (SYNGENE.NS) NSE
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In INR
Address
Biocon SEZ, Biocon Park,
Bengaluru, 560099
India
Phone
91 80 2808 2808
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6510
First IPO Date
August 11, 2015
| Name | Title | Pay | Year Born |
| Peter James Jonathan Bains | Chief Executive Officer, MD & Director | 400,000 | 1957 |
| Kiran Mazumdar-Shaw | Executive Chairperson | 9.95M | 1953 |
| Mrinal Kammili | Head of Translational and Clinical Research | 0 | N/A |
| Subhendu Kumar Mohanty | Head of Chemistry | 0 | N/A |
| Surender Kumar Sharma | General Counsel | 0 | 1975 |
| Nandini Agarwal | Investor Relations Officer | 0 | N/A |
| Chethan Yogesh | Company Secretary & Compliance Officer | 0 | N/A |
| Gaurav Kushwaha | Chief Technology Officer | 0 | N/A |
| Jayashree Aiyar | Chief Scientific Officer | 0 | N/A |
| Priyaranjan Pattanaik | Head of Biology | 0 | N/A |
| Sandeep Nair | Head of Corporate Communications | 0 | N/A |
| Deepak Jain | Chief Financial Officer | 0 | N/A |
| Ajay Tandon | Head of Strategy & Corporate Development | 0 | N/A |
| Krishnan | Head of Investor Relations | 0 | N/A |
| Pramuch Goel | Head of Corporate Affairs | 0 | N/A |
| Rohtash Kumar | Head of CDMO, Small & Large Molecule | 0 | N/A |
Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The company's comprehensive service portfolio begins with discovery chemistry, encompassing medicinal and synthetic chemistry, library and peptide synthesis, biomolecule research, organic electronic materials, and specialized computational and analytical chemistry. In discovery biology, capabilities extend to recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK (Drug Metabolism and Pharmacokinetics), in vivo pharmacology, toxicology, and the development of biologicals. Syngene provides a full spectrum of toxicology services, from exploratory and in vitro studies to genetic, developmental, and reproductive toxicology, alongside acute, sub-chronic, and chronic toxicity assessments. Their development services include chemical, formulation, analytical, and clinical development, as well as commercial manufacturing. They also support crucial stages like lead generation, preclinical development, API (Active Pharmaceutical Ingredient) synthesis, and finished drug product development. For clinical trials, Syngene offers robust support, covering trial management, pharmacokinetic analysis/bioanalytical services, central laboratory operations, biometrics and clinical data management, regulatory affairs, medical monitoring, pharmacovigilance, and medical writing. Additionally, the company specializes in emerging drug modalities, such as peptides, oligonucleotide synthesis, antibody-drug conjugates (ADCs), PROTACs, and CAR T-cell therapies. Serving a diverse clientele that spans pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries, Syngene has established key collaborations with entities like Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc. Incorporated in 1993 and headquartered in Bengaluru, India, Syngene International Limited operates as a subsidiary of Biocon Limited.